About CATC
Dear colleague,
Welcome to the Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC), a key event dedicated to exploring recent advancements in medical science. This symposium brings together scientists, clinicians, and industry professionals to discuss the latest developments in T cell therapy and cellular engineering.
Over the course of September 24-25, 2024, attendees will have the opportunity to engage with a comprehensive program designed to foster knowledge exchange and collaboration. The symposium will feature keynote presentations from renowned experts, who will provide insights into the most recent research findings and clinical applications. These presentations will cover a range of topics, including advancements in CAR-T cell therapy, novel T cell receptor engineering techniques, and the application of CRISPR and other gene-editing technologies in cellular therapy.
In addition to keynote speeches, the symposium will include a series of focused research presentations. These sessions will highlight innovative approaches to overcoming challenges in the field, such as targeting solid tumors, enhancing the persistence and efficacy of engineered T cells, and developing strategies to navigate the tumor microenvironment. Researchers will also present on the latest advancements in synthetic biology tools that are driving precision medicine forward.
Networking opportunities are a key component of the symposium, with dedicated sessions for one-on-one meetings, poster presentations, and social events. These interactions will facilitate the exchange of ideas, the establishment of professional connections, and the potential for future collaborations that can drive further innovation in the field.
An industry exhibition will also be featured, showcasing the latest products and services from leading biotech companies. Attendees will have the chance to explore new technologies, discuss potential collaborations, and gain insights into the commercial landscape of T cell therapy and cellular engineering.
We are confident that the CATC will provide an invaluable experience for all participants, fostering collaboration, innovation, and advancement in the field.
Join us to connect with peers, learn from the pioneers in the field, and contribute to the future of personalized medicine and transformative treatments for cancer and genetic disorders.
On behalf of the organizing committee.
Organising Committee:
Sine Reker Hadrup is Professor and Head of Section at the Department of Health Technology at the Technical University of Denmark (DTU). She is widely recognized for her groundbreaking work and in in immunotherapy and T-cell research, and innovative technologies to explore T cell recognition
Academic Background and Career:
Sine graduated as a human biologist from the University of Copenhagen in 2002 and earned her Ph.D. there in 2006. She further honed her expertise during a postdoctoral stay at the Netherlands Cancer Institute and as a group leader at the National Center for Cancer Immune Therapy at Herlev Hospital. Since joining DTU in 2014, she has made significant strides in immunotechnologies and cancer immunotherapy, achieving a professorship in 2017.
Research and Achievements:
Sine's research is centered on training the immune system’s T-cells to better recognize and attack cancer cells. Her innovative approach involves using a technological platform to analyze T-cell interactions with cancer cells, which has been instrumental in developing personalized T-cell therapies. This work is aimed at enhancing the body’s natural ability to fight cancer, providing treatments specifically targeted towards cancer. Sine's research team also has significant interest and activities to understand basic T-cell receptor and target (pMHC) interactions, including ways to describe and modify these. This work is also centered on understanding the T cell roll in autoimmune diseases.
In recognition of her contributions, Sine received the prestigious EliteForsk prize, awarded by the Danish Ministry of Higher Education and Science, and two ERC grant (starting and consolidator) highlighting her research’s impact and excellence in the field of health technology (DTU).
Professional Contributions:
Sine is also an entrepreneur, having co-founded ImmuMap and Tetramer Shop, which provide tools and reagents developed from her research, and PokeAcell, focuses on personalized T-cell therapy.
Özcan Met is heading the Cell Therapy Unit at the National Center for Cancer Immune Therapy, Denmark since 2010, directing all operational activities required for the manufacturing of cellular products intended for use in clinical trials. As Head of Cell Therapy, he has been responsible for the release of more than 200 cell therapy products in phase I, II, and III immunotherapy clinical trials.
Özcan Met has more than 20 years of research experience in tailoring the immune system to combat cancer and is leading a team at the cutting edge in the development of novel cell-based technologies for patient treatment.
Maria Ormhøj is an Assistant Professor in the Department of Health Technology at the Technical University of Denmark (DTU). Her academic and research pursuits are primarily centered around experimental and translational immunology, with a significant focus on CAR-T cancer therapy.
Academic Background and Career:
Maria holds a Ph.D. in Biomedicine, and her postdoctoral work has been distinguished by innovative research expansion strategies to improve CAR-T and natural occurring T cells for targeting cancer. She is involved in cutting-edge research and development programs to armor CAR-T cells, design payloads to induced antigen spreading, and in-vivo modifications of CAR-T cells.
Research and Achievements:
At DTU, Maria's research is crucial in advancing our understanding of T-cell engineering and cancer immunotherapy. She has been instrumental in projects aimed at improving cell therapy techniques to treat otherwise incurable brain tumors, supported by the Independent Research Fund Denmark. Her work not only contributes to scientific knowledge but also holds potential for clinical applications
Professional Contributions:
Maria is actively engaged in the academic community at DTU, contributing to various collaborative research projects and publications. Her work is highly regarded by peers, and she frequently participates in symposiums and conferences, sharing insights and advancements in health technology and immunology.
Getting there
Anker Engelunds Vej 1
Building 101A
2800 Kgs. Lyngby
Denmark
By bus or train
Several busses cross or pass the DTU campus area and Lyngby Station is just 2 km away with even more bus connections.
Access the Journey Planner to see how to get to DTU with public transportation from the airport and the main stations of Copenhagen.
By car
Currently, there is some roadwork around DTU, so check Google regarding access to DTU and parking.
By taxi
From the airport it will cost you about DKK 600 (EUR 80) and from downtown Copenhagen about DKK 350 (EUR 47) .
To order a taxi, please call one of the following numbers:
- Amager-Øbro Taxa: tel. 3251 5151
- DanTaxi: tel. 4848 4848
- Taxa 4x35: tel. 3535 3535